<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282668</url>
  </required_header>
  <id_info>
    <org_study_id>TAS1440-01</org_study_id>
    <nct_id>NCT04282668</nct_id>
  </id_info>
  <brief_title>A Study of TAS1440 With ATRA in Subjects With r/r AML</brief_title>
  <official_title>A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination With All-Trans Retinoic Acid (ATRA) in Subjects With Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics,&#xD;
      pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent&#xD;
      and in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid&#xD;
      leukemia (AML) who have relapsed or are refractory (r/r) to prior treatment. The study&#xD;
      duration is expected to be approximately 30 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate: Number of participants with complete remission (CR), complete remission with incomplete blood count recovery (CRi), partial remission (PR) and complete remission with partial hematological recovery (CRh)</measure>
    <time_frame>Approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival: Time from the date of the first dose until death due to any cause</measure>
    <time_frame>Approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Area under the curve (AUC)</measure>
    <time_frame>Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Minimum plasma concentration (Cmin)</measure>
    <time_frame>Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Half-life (t1/2)</measure>
    <time_frame>Up to Day 8 of Cycle 1 and Cycle 2 (28 days per cycle)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>TAS1440</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS1440 + ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS1440</intervention_name>
    <description>Form: Capsule Route of Administration: Oral</description>
    <arm_group_label>TAS1440</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS1440 + ATRA</intervention_name>
    <description>Form: Capsule Route of Administration: Oral</description>
    <arm_group_label>TAS1440 + ATRA</arm_group_label>
    <other_name>Tretinoin</other_name>
    <other_name>Vesanoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a projected life expectancy of at least 12 weeks and be in stable condition to&#xD;
             complete 1 full cycle (4 weeks) of treatment.&#xD;
&#xD;
          2. Have histological confirmation of AML by World Health Organization (WHO) 2016 criteria&#xD;
             and who have failed all other available conventional therapies.&#xD;
&#xD;
          3. Have a peripheral blood or bone marrow blast count &gt;5% at the time of enrollment.&#xD;
&#xD;
          4. Have disease that:&#xD;
&#xD;
               1. is refractory to standard induction chemotherapy, including but not limited to&#xD;
                  anthracycline and cytarabine combination therapy, or&#xD;
&#xD;
               2. has relapsed after anthracycline and cytarabine therapy or stem cell transplant&#xD;
                  (SCT), or&#xD;
&#xD;
               3. is refractory to or has relapsed after a front-line regimen containing a&#xD;
                  hypomethylating agent, alone or in combination.&#xD;
&#xD;
          5. Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 1.&#xD;
&#xD;
          6. Have adequate renal function as demonstrated by a serum creatinine ≤1.5 × upper limit&#xD;
             of normal (ULN) or calculated creatinine clearance (by the standard Cockcroft-Gault&#xD;
             formula) of ≥60 mL/min.&#xD;
&#xD;
          7. Have adequate liver function as demonstrated by the following:&#xD;
&#xD;
               1. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;3 × upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               2. AST and ALT &lt;5 × ULN (if considered due to leukemic organ involvement).&#xD;
&#xD;
          8. Women of child-bearing potential (according to recommendations of the Clinical Trial&#xD;
             Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a&#xD;
             negative pregnancy test at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known clinically active central nervous system leukemia.&#xD;
&#xD;
          2. BCR-ABL-positive leukemia.&#xD;
&#xD;
          3. Diagnosis of acute promyelocytic leukemia (M3 AML or APML or APL).&#xD;
&#xD;
          4. Second malignancy currently requiring active therapy, except breast or prostate cancer&#xD;
             stable on or responding to endocrine therapy.&#xD;
&#xD;
          5. Grade 3 or higher graft versus host disease (GVHD), or GVHD requiring treatment with&#xD;
             either:&#xD;
&#xD;
               1. a calcineurin inhibitor, or&#xD;
&#xD;
               2. prednisone more than 5 mg/day (Note: Prednisone at any dose for other indications&#xD;
                  is allowed).&#xD;
&#xD;
          6. Total serum bilirubin ≥1.5 × ULN (except for subjects with Gilbert's Syndrome for whom&#xD;
             direct bilirubin is &gt;2.5 × ULN), or liver cirrhosis, or chronic liver disease&#xD;
             Child-Pugh Class B or C.&#xD;
&#xD;
          7. Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis&#xD;
             C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis&#xD;
             titer being treated with antivirals is allowed. For subjects considered at risk of&#xD;
             viral exposure, serologies should be used to establish negativity.&#xD;
&#xD;
          8. Known significant mental illness or other condition such as active alcohol or other&#xD;
             substance abuse or addiction that, in the opinion of the investigator, predisposes the&#xD;
             subject to high risk of non-compliance with the protocol.&#xD;
&#xD;
          9. Myocardial impairment of any cause (eg, cardiomyopathy, ischemic heart disease,&#xD;
             significant valvular dysfunction, hypertensive heart disease, or congestive heart&#xD;
             failure) resulting in heart failure by New York Heart Association (NYHA) Criteria&#xD;
             (Class III or IV staging).&#xD;
&#xD;
         10. Screening 12-lead echocardiogram with measurable QTc interval (according to either&#xD;
             Fridericia's or Bazett's correction) of &gt;480 milliseconds.&#xD;
&#xD;
         11. Active, uncontrolled infection. Participants with an infection receiving treatment&#xD;
             (antibiotic, antifungal, or antiviral treatment) must be afebrile and hemodynamically&#xD;
             stable for ≥72 hours before enrollment.&#xD;
&#xD;
         12. Non-AML-associated pulmonary disease requiring &gt;2 liters per minute (LPM) oxygen.&#xD;
&#xD;
         13. Proliferative AML with total white blood cells &gt; 20,000/uL&#xD;
&#xD;
         14. Any other condition that puts the participant at an imminent risk of death.&#xD;
&#xD;
         15. Treated with any investigational therapy within 2 weeks of the first dose of study&#xD;
             treatment.&#xD;
&#xD;
         16. Inability to swallow oral medication.&#xD;
&#xD;
         17. Known hypersensitivity to ATRA, any of its components, or other retinoids.&#xD;
&#xD;
         18. Known sensitivity to parabens.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Lowder, MD</last_name>
    <role>Study Director</role>
    <affiliation>Astex Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joyce Alejo-Stone</last_name>
    <phone>925-560-2886</phone>
    <email>joyce.alejo-stone@astx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Lowder, MD</last_name>
    <phone>925-560-2894</phone>
    <email>james.lowder@astx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharad Khurana</last_name>
      <email>skhurana@arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylee Fleig</last_name>
      <phone>502-629-3681</phone>
      <email>Kylee.Fleig@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical School</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-865-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Mattour</last_name>
      <phone>888-734-5322</phone>
      <email>amattou1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Traer, PhD</last_name>
      <phone>503-494-5058</phone>
      <email>traere@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asya Varshavsky</last_name>
      <phone>215-728-3088</phone>
      <email>asyanina.varshavskyyanovsky@fccc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Pearson</last_name>
      <phone>214-370-1000</phone>
      <email>edward.pearson1@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesid A Valero</last_name>
      <phone>713-794-4364</phone>
      <email>yalvarad@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Yesid A Valero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarisa Brown</last_name>
      <phone>206-667-2523</phone>
      <email>cnbrown@fredhutch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

